Dr. Steven St. Peter is one of our founders and has served as our President and Chief Executive Officer since September 2012. He has been a member of our Board of Directors since December 2010 and served as the Chairman of our Board of Directors from December 2010 to September 2012. Dr. St. Peter was a Managing Director of MPM Asset Management LLC from January 2004 to May 2012, where he focused his investments on both venture and buyout transactions across the pharmaceuticals and medical technology industries. He has previous investment experience from Apax Partners and The Carlyle Group, two private equity firms. Dr. St. Peter was previously an Assistant Clinical Professor of medicine at Columbia University. He received his M.D. from Washington University and completed his residency and fellowship at the Hospital of the University of Pennsylvania. Prior to his medical training, he was an investment banker at Merrill Lynch. Dr. St. Peter also holds an M.B.A. from the Wharton School of Business at the University of Pennsylvania and a B.A. in Chemistry from the University of Kansas. Dr. St. Peter has served as a director of PharmAthene, Inc., a publicly-traded biodefense company, since August 2007 and is currently a member of its governance and nominating committee. Dr. St. Peter has also served as a member of the Board of Directors of the Kansas City Area Life Sciences Institute since March 2014 and as a member of the Board of Directors of the Greater Kansas City Foundation since November 2015. Dr. St. Peter’s previous board experience includes MPM Acquisition Corp., Proteon Therapeutics, Inc., Rhythm Pharmaceuticals, Inc. and Syndax Pharmaceuticals, Inc.

What if veterinarians could apply advances in human health to provide better therapeutic options for dogs and cats? At Aratana Therapeutics, we’re asking more than “what if” — we’re asking how and when. As a new kind of animal health company, our sole focus is on how to solve unmet and underserved medical needs in pets with serious diseases. We are working to bring together the intersection of advances in human biotechnology and veterinary medicine to develop solutions with the goal to help raise the standard of care for medical conditions in pets. As we hope our portfolio indicates, we’re passionate about giving veterinarians, pet owners and their pets therapeutic options based on cutting-edge science, as well as proven safety and effectiveness studies in pets. We are committed to evidence-based medicine. We run pilot and pivotal studies and analyze data to evaluate both the safety and efficacy of novel therapeutics that have the potential to give pets with serious conditions a new beginning. Ultimately, these studies are crucial in helping to improve medical treatments and outcomes for pets. Aratana has specialized experience to move new pet therapeutics through the process of formulation development, pre-clinical and clinical evaluation, regulatory approval, manufacturing and commercialization. In addition to our approved or licensed therapeutics, we have several novel therapeutics in development for pain, viral diseases, allergy and cancer that have the potential to improve the quality of lives for dogs and cats.